Estimates of the walking distance in multiple sclerosis patients and their effect on the EDSS [7]

Journal of Neurology

Volumn 253, Issue 5, 2006, Pages 666-667

  Ringel, I ^a   Zettl, U K ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; CLINICAL FEATURE; EVALUATION; EXPANDED DISABILITY STATUS SCALE; HUMAN; LETTER; MULTIPLE SCLEROSIS; POPULATION MODEL; PRIORITY JOURNAL; SEX RATIO; STATISTICAL ANALYSIS;

ADULT; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; WALKING;

EID: 33745043790     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-006-0049-7     Document Type: Letter

References (11)

1. Albrecht H, Wotzel C, Erasmus LP, Kleinpeter M, Konig N, Pollmann W (2001) Day-to-day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameter. Mult Scler 7:105-109
2. Fischer JS, Rudick RA, Cutter GR, Reingold SC (1999) The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 5:244-250
3. International Working Group for treatment Optimization in MS (2004) Treatment optimization in multiple sclerosis: report of an international consensus meeting. Eur J Neurol 11:43-47
4. Jeffery D, Bashir K, Buchwald L, Coyle P, Freedman M, Markowitz C, Rammohan K, Reder T, Sharief M, Wolinsky J (2002) Optimizing immunomodulatory therapy for MS patients: an integrated management model. J Neurol Sci 201:89-90
5. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33:1444-1452
6. Multiple Sclerosis Therapy Consensus Group (2004) Escalating Immunotherapy of Multiple Sclerosis - New Aspects and practical Applications. J Neurol 251:1329-1339
7. Noseworthy JH (1994) Clinical scoring methods for multiple sclerosis. Ann Neurol 36(Suppl):80-85
8. Rio J, Nos C, Tintore M, Borras C, Galan I, Comabella M, Montalban X (2002) Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 52:400-406
9. Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD (2002) Quantitative functional measures in MS: what is a reliable change? Neurology 58:1294-1296
10. Sharrack B, Hughes RA (1997) Reliability of distance estimation by doctors and patients: cross sectional study. BMJ 315:1652-1654
11. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112:133-146